Idiopathic Thrombocytopenic Purpura Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Idiopathic Thrombocytopenic Purpura Clinical Trials Market Report Overview
The idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) clinical trial market research report provides an overview of the clinical trials, including top-line data. The data highlights the number of trial numbers and their average enrolment in top countries conducted across the globe. Furthermore, the clinical trials for Keratoconjunctivitis are elaborated by region, country (G7 & E7), phase, trial status, end points status, and sponsor type, in this report.
Key Regions | Asia-Pacific, Europe, North America, Middle East & Africa, and South & Central America |
Key Countries | China, The US, The UK, Germany, France, Russia, Spain, Australia, Italy, and the Netherlands |
Key Sponsor Types | Institution, Company, and Government |
Leading Sponsors | GSK plc, Rigel Pharmaceuticals Inc, Amgen Inc, Novartis AG, Eisai Co Ltd, AstraZeneca Plc, Jiangsu Hengrui Medicine Co Ltd, Sanofi, and Swedish Orphan Biovitrum AB |
Idiopathic Thrombocytopenic Purpura Clinical Trials Market Segmentation by Regions and Countries
The key regions in the idiopathic thrombocytopenic purpura clinical trials market are Asia-Pacific, Europe, North America, the Middle East & Africa, and South & Central America. Of all the clinical trials conducted on idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura), as of January 2023, more than 40% of the clinical trials were conducted in Asia-Pacific, followed by Europe.
In a country-wise analysis, as of January 2023, China has the highest number of idiopathic thrombocytopenic purpura clinical trials, followed by the US, the UK, Germany, France, Russia, Spain, Australia, Italy, and the Netherlands.
G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, the UK has the highest proportion of idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) to hematological disorders clinical trials as of January 2023. Out of all the clinical trials conducted in the G7 countries, the majority were in the US.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, China has the highest proportion of idiopathic thrombocytopenic purpura (immune thrombocytopenic purpura) to hematological disorders clinical trials as of January 2023. Also, most of the clinical trials were conducted in China.
Idiopathic Thrombocytopenic Purpura Clinical Trials Analysis by Regions, 2023 (%)
Buy The Full Report For More Regional Insights Into The Idiopathic Thrombocytopenic Purpura Clinical Trials Market, Download A Free Report Sample
Idiopathic Thrombocytopenic Purpura Clinical Trials Market Segmentation by Sponsor Types
The key sponsor types in the idiopathic thrombocytopenic purpura clinical trials market are institution, company, and the government. Out of them, the company sponsor type dominates the market, followed by institution.
Idiopathic Thrombocytopenic Purpura Clinical Trials Market Analysis by Sponsor Types, 2023 (%)
Buy The Full Report For More Sponsor Type Insights Into The Idiopathic Thrombocytopenic Purpura Clinical Trials Market, Download A Free Report Sample
Idiopathic Thrombocytopenic Purpura Clinical Trials Market - Competitive Landscape
Some of the leading sponsors in the idiopathic thrombocytopenic purpura clinical trials market are GSK plc, Rigel Pharmaceuticals Inc, Amgen Inc, Novartis AG, Eisai Co Ltd, AstraZeneca Plc, Jiangsu Hengrui Medicine Co Ltd, Sanofi, and Swedish Orphan Biovitrum AB. GSK plc has conducted the highest number of idiopathic thrombocytopenic purpura clinical trials and is followed by Rigel Pharmaceuticals Inc and Amgen Inc.
Idiopathic Thrombocytopenic Purpura Clinical Trials Market Analysis by Sponsors, 2023 (%)
Buy The Full Report To Know More About The Leading Players In The Idiopathic Thrombocytopenic Purpura Clinical Trials Market, Download A Free Report Sample
Segments Covered in the Report
Idiopathic Thrombocytopenic Purpura Clinical Trials Regional Outlook (2023)
- Asia-Pacific
- North America
- Europe
- Middle East & Africa
- South & Central America
Idiopathic Thrombocytopenic Purpura Clinical Trials Country Outlook (2023)
- China
- The US
- The UK
- Germany
- France
- Russia
- Spain
- Australia
- Italy
- Netherlands
Idiopathic Thrombocytopenic Purpura Clinical Trials Sponsor Type Outlook (2023)
- Institution
- Company
- Government
Scope
- The report provides a snapshot of the global clinical trials landscape
- The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and end-point status
- The report reviews the top companies involved and enlists all trials (trial title, phase, and status) pertaining to the company
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with reasons for unaccomplishment
- The report provides enrollment trends for the past five years
- The report provides the latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regard to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top-level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in the global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional, and country level
Rigel Pharmaceuticals Inc
Amgen Inc
Novartis AG
Eisai Co Ltd
AstraZeneca Plc
Jiangsu Hengrui Medicine Co Ltd
Sanofi
Swedish Orphan Biovitrum AB
3SBio Inc
Table of Contents
Table
Figures
Frequently asked questions
-
Which are the key regions in the idiopathic thrombocytopenic purpura clinical trials market?
The key regions in the idiopathic thrombocytopenic purpura clinical trials market are Asia-Pacific, Europe, North America, the Middle East & Africa, and South & Central America.
-
Which are the key countries in the idiopathic thrombocytopenic purpura clinical trials market?
The key countries in the idiopathic thrombocytopenic purpura clinical trials market are China, the US, the UK, Germany, France, Russia, Spain, Australia, Italy, and the Netherlands.
-
Who are the key sponsor types in the idiopathic thrombocytopenic purpura clinical trials market?
The key sponsor types in the idiopathic thrombocytopenic purpura clinical trials market are institution, company, and the government.
-
Who are the leading sponsors in the idiopathic thrombocytopenic purpura clinical trials market?
Some of the leading sponsors in the idiopathic thrombocytopenic purpura clinical trials market are GSK plc, Rigel Pharmaceuticals Inc, Amgen Inc, Novartis AG, Eisai Co Ltd, AstraZeneca Plc, Jiangsu Hengrui Medicine Co Ltd, Sanofi, and Swedish Orphan Biovitrum AB.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.